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Abstract
Phthalates and bisphenol A are environmental endocrine-disrupting chemicals used widely in
common consumer products. There is increasing concern about human exposure to phthalates and
bisphenol A due to the potential adverse effects related to the anti-androgenic activity of
phthalates and estrogenic activity of bisphenol A. In assessing environmental exposure to
phthalates and bisphenol A, it is essential to have a validated analytical method that can quantify
trace concentrations of phthalate metabolites and bisphenol A in humans. In this study, we
developed and validated an accurate, sensitive, and robust LC-MS/MS method to simultaneously
quantify 5 phthalate monoester metabolites, including mono-methyl phthalate, mono-ethyl
phthalate, mono-butyl phthalate, mono-benzyl phthalate, mono-2-ethylhexyl phthalate, and
bisphenol A in human urine. In this method, the phthalate metabolites and bisphenol A, along with
their isotope labeled internal standards, were extracted from 200 μl of human urine using
automated off-line solid phase extraction. The analytes were quantitatively determined using LC-
MS/MS operated in negative electrospray ionization multiple reaction-monitoring mode. The limit
of quantification was 0.3 ng/ml for mono-methyl phthalate, mono-ethyl phthalate, mono-benzyl
phthalate and bisphenol A, and 1 ng/ml for mono-butyl phthalate and mono-2-ethylhexyl
phthalate. The precision and accuracy were well within the acceptable 15% range. This validated
method has been used successfully in assessing exposure to phthalates and bisphenol A in humans.
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Introduction
Phthalates and Bisphenol A (BPA) are high-production chemicals commonly used in plastic
products [1]. Phthalates are used in many household and personal care products, toys, and
medical supplies, as well as in plastics to improve flexibility. BPA is a main ingredient in
plastics and resins, and is used in a variety of consumer products including water bottles, the
inside lining of cans, and in cash register receipt paper. The ubiquitous use of phthalates and
BPA results in widespread human exposure. The U.S. Centers for Disease Control and
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Prevention (CDC) has reported measurable concentrations of phthalate metabolites such as
mono-ethyl phthalate (MEP), mono-butyl phthalate (MBP), and mono-benzyl phthalate
(MBzP) in > 97%, and mono-2-ethylhexyl phthalate (MEHP) and mono-methyl phthalate
(MMP) in > 75% of the US population [2,3]. Detectable levels of BPA have also found in
urine in 92% of Americans [4].
Phthalates and BPA are known to be endocrine disruptors, man-made chemicals that disrupt
the endocrine system by competing with endogenous hormones by binding to receptors or
by altering the synthesis and metabolism of these hormones. Numerous laboratory animal
studies and some human epidemiological studies have demonstrated that phthalates and
BPA can interfere with human hormones, potentially creating problems with health and
normal growth and development. Exposure to phthalates and BPA has been associated with
altered hormone levels, reproductive effects (male fertility), precocious puberty in pubertal
girls, increased incidence of chronic disease, and a possible role in the development of
cancer [5-9].
Once in the body, phthalates are rapidly metabolized by hydrolysis to their corresponding
monoester metabolites, which are then further metabolized or eliminated in the urine as
glucuronides. Phthalates are ubiquitous both in the environment and in the analytical
laboratory, where they are present in analytical instruments, gloves, plastic tubing, solvents
and air. To prevent potential sample contamination from phthalates in the environment,
phthalate exposure assessment in humans has been chiefly conducted by biomonitoring of
phthalate metabolites in urine. The ingested BPA is mainly conjugated with glucuronic acid
and eliminated in the urine [2,3]. Urinary levels of BPA, including both conjugated and
unconjugated forms, are often monitored to reflect exposure to this chemical in humans [4].
Various analytical methods have been developed for measuring BPA or phthalate monoester
metabolites separately in urine, mostly using gas chromatography coupled with mass
spectrometry (GC-MS) [10, 11] and liquid chromatography coupled with mass spectrometry
(LC-MS) or tandem MS (LC-MS/MS) [11-18]. LC-MS/MS methods, which combine high
selectivity and sensitivity, show an advantage over GC-MS methods because of simple
sample preparation without the need for derivatization. The earlier methods for the
determination of phthalate metabolites or BPA in human urine by LC-MS/MS combined
with manual or automated offline solid phase extraction (SPE) usually required 1ml of urine
[13-15]. The on-line SPE LC-MS/MS methods using smaller sample volume (0.1 ml)
demonstrated high sensitivity with limit of detection (LOD) value of 0.4 ng/ml for BPA and
ranging from 0.15-1.1, 0.4-0.7, 0.4-0.6, 0.11-0.3, 0.9-1.1 ng/ml for MMP, MEP, MBP,
MBzP and MEHP, respectively [16-18]. Although these on-line SPE LC-MS/MS methods
are considered the most advanced for urine biomonitoring studies, they are limited by their
high cost and therefore not practical for many studies. Due to the increasing concern on the
endocrine disrupting chemicals, such as phthalates and BPA, and the needs to assess their
exposure to individuals, it is essential to have a sensitive, low cost and efficient analytical
method that can quantify these chemicals or their metabolite levels simultaneously in human
urine. However, to our knowledge, there is no single analytical method reported utilizing
LC-MS/MS for the simultaneous determination of BPA and phthalate monoester metabolites
in human urine. Instead, studies on assessing human exposure to BPA and phthalate have
been using GC-MS for BPA and LC-MS/MS for phthalate metabolites or two different LC-
MS/MS methods to quantify phthalate metabolites or BPA separately [19-24]
In this paper, we have developed a simple, sensitive and low-cost LC-MS/MS method
combined with automated off-line SPE to measure the concentrations of five phthalate
monoester metabolites: MMP, MEP, MBP, MBzP and MEHP, and BPA simultaneously in
human urine samples. The method is validated in terms of linearity, limit of quantification
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(LOQ), accuracy, precision, stability, and matrix effect. After successful development and
validation of this method, it was utilized in analyzing a set of human urine samples collected
for evaluating potential BPA and phthalates exposure. The accuracy, reproducibility, and
rigor of this assay have been demonstrated in this analysis.
1. Experimental
1.1 Materials
MMP, MEP, MBP, MBzP and MEHP were purchased from Accustandard (New Haven, CT,
USA). BPA, 4-methylumbelliferone, 4-methylumbelliferyl glucuronide and β-
glucuronidase/sulfatase (Helix pomatia, H1), LC-MS grade ammonium acetate, acetic acid,
and formic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). The isotope
labeled internal standards 13C12-BPA (99%), 13C4-4-methylumbelliferone, 13C4-mono-
methyl phthalate (13C4-MMP), 13C4-mono-ethyl phthalate (13C4-MEP), 13C4-mono-butyl
phthalate (13C4-MBP) and 13C4-mono-benzyl phthalate (13C4-MBzP) solutions were
purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). D4-mono-2-
ethylhexyl phthalate (D4-MEHP) was purchased from C/D/N Isotopes, Inc. (Quebec,
Canada). HPLC-grade reagents, including acetonitrile, methanol, and water were purchased
from JT Baker (Center Valley, PA, USA). Frozen human urine (pooled from 20 individuals)
were shipped from Bioreclamation (Hicksville, NY, USA) under dry ice and stored at −20
°C until use. All the glassware used in the experiments was methanol-rinsed and dried.
2.2 Instrument
The HPLC system consisted of a Shimadzu LC SCL-10AVP solvent delivery unit, an online
solvent degasser, a gradient mixer and a system controller (Shimadzu Scientific, Columbia,
MD, USA). A CTC-PAL autosampler (LEAP Technologies, Carrboro, NC, USA) was used
to inject samples. The mass spectrometer was API 4000 LC-MS/MS system (AB SCIEX,
Framingham, MA, USA) equipped with a Turbo V IonSpray ionization source. Analyst
software version 1.4.1 from AB SCIEX was used for data acquisition and processing.
2.3 LC conditions
The chromatographic separation was performed on a Thermo Betasil phenyl column (50 mm
× 2.1 mm, 3 μm particle size, Thermo Electron, Bellefonte, PA, USA) maintained at the
ambient temperature with a precolumn inline filter (0.5 μm, Sigma-Aldrich, St. Louis, MO,
USA). The CTC-PAL Leap cooling unit was set at 4 °C, and the sample injection volume
was 10 μl. The mobile phase was 0.1% acetic acid in water (A) and 0.1% acetic acid in
acetonitrile (B) at a flow rate of 220 μl/min. The mobile phase gradient was as follows: 5%
B for 2.0 min; linear increased to 100% B from 2.0 to 7.0 min, and then maintained at 100%
B from 7.0 to 9.0 min, went back to 5% B from 9.0 to 10.0 min and maintained at this
proportion from 10.0 to 12.0 min.
2.4 Mass spectrometer conditions
The electrospray probe was operated in the negative ion mode. Ultra pure nitrogen (N2,
99.995%, Airgas, Radnor, PA, USA) was used as nebulizer, curtain, and collision gas. The
optimum operating conditions of the electrospray ionization (ESI) were as follows:
nebulizing gas (GS1), turbo gas (GS2), curtain gas (CUR), collision activated dissociation
gas (CAD), turbo-spray voltage and turbo temperature were set to 20, 18, 10, 10 psi, −4.5
kV and 440 °C, respectively. All analytes were quantified using multiple reaction-
monitoring (MRM) mode. The mass spectrometer was operated in unit resolution for both
Q1 and Q3 in MRM mode, with a dwell time of 150 ms per MRM channel with a 5 ms
pause between scans. The transitions monitored were as follows: MMP (precursor ion →
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product ion, m/z 179 →107), 13C4-MMP (m/z 183 →79), MEP (m/z 193 →121), 13C4-
MEP (m/z 197 →79), MBP (m/z 221 →77), 13C4-MBP (m/z 225 →151), MBzP (m/z 255
→107), 13C4-MBzP (m/z 259 →107), MEHP (m/z 277 →134), d4-MEHP (m/z 281
→138), BPA (m/z 227 →133), 13C12 BPA (m/z 239 →224). To monitor the extent of the
enzymatic reaction, 4-methylumbelliferone, 13C4-4-methylumbelliferone and 4-
methylumbelliferyl glucuronide were acquired at m/z 175 →133, m/z 179→135 and m/z
351→175, respectively.
The peak areas of analytes and their IS’s were determined using analyst version 1.4.1.
Identification of each analyte was based on its retention time and mass spectrum.
Additionally, the stable isotope ISs served as a tool for the confirmation of the analytes in
unknown samples by providing a chromatographic reference for each peak selection. For
each analytical batch, a calibration curve containing 5 phthalate monoesters and BPA with
slope, intercept and correlation coefficient (r) was derived from weighted (1/x) linear least
squares regression of the peak area ratio (analyte: IS) versus the concentration of the
standards. The regression equation from the calibration curve was used to back-calculate the
measured concentration of each standard and quality control (QC). The results were
compared to the theoretical concentrations to obtain the accuracy, expressed as a percentage
of the theoretical value, for each standard and QC measured. The standard calibration was
injected before and after all samples, including blanks, QCs and unknowns, to monitor
sensitivity changes.
Due to the lack of a phthalate-and BPA-free urine matrix, levels in QCs were blank-
corrected. Each batch of 30 samples included 3 low QC (QCL) at 10 ng/ml, 3 high QC
(QCH) at 100 ng/ml and 3 reagent blanks. Trace concentrations of MBP and MEHP were
detected in reagent blanks, and sample concentrations were subtracted from blank values for
these 2 compounds. Samples with concentrations above the highest calibrator were diluted
with water into calibration range and re-extracted. Concentrations below the limit of
quantitation (LOQ) were substituted with a value equal to the LOQ divided by 2 or by the
square root of 2 for the calculation of mean and geometric mean, respectively. All the
reported urinary metabolite values were not adjusted for creatinine.
2.5 Preparation of standard and QC samples
The initial stock standard solutions of BPA were prepared by dissolving accurately weighed
standard compounds in methanol and quantitatively transferring this solution to a 10-ml
volumetric flask. The stock standard solutions of the 5 phthalate monoesters were prepared
in acetonitrile. The initial stock standard solutions were stored in amber glass vials at −20 °C
until use. The intermediate standard solutions for BPA and 5 phthalate monoesters were
prepared by serial dilutions of the initial stock standard solution with methanol. The
intermediate IS solution of 13C12-BPA, 13C4-labeled phthalate monoester standards and D4-
MEHP was prepared by aliquoting the commercial standard solution (100 μg/ml in
acetonitrile) to each 10 ml glass volumetric flask and diluting by volume with methanol to
give a final concentration of 5 μg/ml for 13C12-BPA and 2 μg/ml for 13C4-labeled phthalate
monoesters and D4-MEHP . All standard solutions were prepared in methanol-rinsed and
dried glassware.
The calibration curves for BPA and 5 phthalate monoesters at ten levels ranged from 0.3 to
200 ng/ml and were prepared by adding aliquots of intermediate standard solutions to water.
The QC samples at two concentration levels 10 (QCL) and 100ng/ml (QCH) were prepared
the same way in pooled human urine. The standards and QCs were stored frozen at −20 °C.
The enzyme solution was prepared fresh daily for each run by dissolving 3.6 mg of β-
glucuronidase/sulfatase (H. pomatia, 1926, 000 units/g of solid) in 1 ml of 1.0 mol/l
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ammonium acetate buffer solution (pH 5.0), and mixing gently to prevent denaturation of
the enzyme.
2.6 Sample preparation
Urine samples were thawed to room temperature and vortexed to ensure homogeneity. Each
of the 200 μl urine sample was then transferred into a glass test tube and mixed with 10 μl
intermediate IS solution (1000 ng/ml of 13C12-BPA and 500 ng/ml of 13C4 labeled phthalate
monoesters), 150 μl ammonium acetate buffer solution (1 mol/l, pH 5.0), 100 μl water, and
20 μl of enzyme solution of β-glucuronidase. The samples were mixed and then incubated at
37 °C for 3 hr in a shaking water bath. Calibration standards, 4 QCL, 4 QCH, and blanks
were also prepared by adding 10 μl intermediate IS solution, 150 μl ammonium acetate
buffer solution and 20 μl of enzyme solution, but 20 μl of acetate buffer was added in QCs
instead of enzyme solution. The samples were then incubated under the same conditions as
the urine samples. After incubation, 10 μl of formic acid was added to each deconjugated
urine samples to stop the enzyme activity, and then 400 μl of water was added. The
calibration standards and QCs were processed in the same way as the deconjugated urine
samples by adding 10 μl of formic acid and diluted with 400 μl of water.
A RapidTrace SPE Workstation (Biotage, Charlotte, NC, USA) and SampliQ SPE cartridges
packed with 200 mg of silica-based bonded C18 material (3 ml) (Agilent Technology, Santa
Clara, CA, USA) were used for extraction. The SPE cartridges were conditioned by
successive washes of 2 ml of methanol and 2 ml of water, followed by the loading of
deconjugated urine samples, calibration standards, or QCs. The cartridges were washed with
1.5 ml of water and eluted with 1 ml of acetonitrile. The eluent was collected and
concentrated to dryness using a TurboVap LV Evaporator (Zymark, Framingham, MA) at
40°C under a gentle nitrogen stream. The dry residue was reconstituted by 150 μl 0.1%
acetic acid in acetonitrile/water (1:9, v/v), and 10 μl of this mixture was injected into the
LC-MS/MS for analysis. The concentration of 4-methylumbelliferone formed from the
enzymatic hydrolysis of 4-methylumbelliferone glucuronide was run in parallel with the
urine samples for the purpose of monitoring the completion of the deglucuronidation
reaction by β-glucuronidase. Reagent blanks, standards, and QCs were analyzed with the
urine samples to ensure accuracy of the data.
2.7 Assay validation
The analytical method was validated to demonstrate the recovery, LOQ, accuracy, and
precision of the measurements. All calibration samples were prepared as described above
using a double blank (extracted water samples without IS), blank (extracted sample with IS)
and water spiked with respective amounts of reference standards.
The linearity of the calibration curve was evaluated from three consecutively prepared
batches at the concentration range 0.3-200 ng/ml. The peak area ratios of analytes and the
corresponding IS were used to calculate the correlation coefficient, intercept and slope.
Fifteen replicates of QC samples generated at concentrations of 10, and 100 ng/ml from runs
on three consecutive days were used to evaluate precision and accuracy at each
concentration level to determine the intra- and inter-day validation. Precision was calculated
as the relative standard deviation (RSD) for both intra-day and inter-day variability and
accuracy as the degree of closeness of the determination value to the true value. The limits
of detection (LODs) were calculated as 3S0, where S0 is the value of the standard deviation
as the concentration approaches zero, and the limit of quantitation (LOQ) was calculated as
3LOD. Acceptable precision was defined by a RSD <15% for the standards, and <20% at
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LOQ. Accuracy was acceptable if the deviation for the standard <15%, and LOQ <20%
compared to the nominal values.
Matrix effect (ME) occurs when the co-elutes from the same sample matrix affects (either
attenuates or enhances) the response of the analyte during quantitation by LC-MS/MS. To
determine the matrix effect of urine on the ESI process, blank urine samples were extracted,
dried, reconstituted and spiked with phthalate monoester metabolites and BPA (post-
extraction spiked sample), then compared to the same level of concentrations of phthalate
monoester metabolites and BPA in neat standard solutions injected directly into LC-MS/MS
using the following equation:
ME% = (Mean post-extraction peak area/Mean neat solution peak area)×100 The values of
ME indicate either ion enhancement (>100%) or ion suppression (<100%). A value of 100%
indicates that there is no matrix effect.
The extraction process recovery was calculated by dividing the area counts of individual
extracted urine samples by the mean area counts of neat standard solutions injected directly
into LC-MS/MS at 2 concentration level (10 and 100 ng/ml) of phthalate metabolites and
BPA.
Stability of standard stock solutions of phthalate monoesters and BPA and their ISs in
methanol used in the preparation of standards and QCs was investigated at both room
temperature and at −20 °C. The stabilities were calculated by comparing mean response
ratios (area of response per unit of concentration) of stability solutions to mean response
ratios of freshly prepared control solutions.
The stabilities of the analytes in spiked urine samples at room temperature (22 °C) for 4 hr,
−20 °C for 90 days and after three freeze/thaw cycles (frozen for 24 h and thawed at room
temperature as one cycle) were evaluated at two concentration levels (10 and 100 ng/ml) in
six replicates. The stability of extracted samples in reconstitution solution at 4 °C (the
temperature of the autosampler) for 2 days was also evaluated. The mean analyte
concentration at each level was compared to each mean concentration determined in the
initial testing. The analytes were considered to be stable if degradation was <10% of the
concentration at day 0.
2.8 Determination of phthalate monoester metabolites and BPA concentrations in human
urine
A total of 50 anonymous adult human urine samples were randomly selected and analyzed
using this LC-MS/MS method. These samples were collected from volunteers participating
in a study aiming to assess their occupational exposures to phthalates. These samples were
collected with approval from Institutional Review Board. We used these materials after
removing all identifiable labels with demographic information. Samples were stored at −20
°C prior to the analysis.
3. Results and Discussion
3.1 Optimization of SPE protocol
Due to the different chemical characteristics of BPA and phthalate monoester metabolites,
the analytical methods developed so far can only monitor either BPA or phthalate monoester
metabolites in human urine using separate analytical methods [11-18]. There were
challenges in both sample preparation and detection of analytes in developing the LCMS/
MS method to detect BPA and phthalate monoester metabolites in human biological matrix
simultaneously. The first challenge was to maintain acceptable recoveries for both BPA and
Chen et al. Page 6
J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
phthalate monoester metabolites (especially MMP) while simultaneously cleaning up
interference from urine as much as possible during the SPE step of sample preparation. This
is especially important for BPA, as its concentrations in the general population are usually
low [3]. However, MMP was easily washed out if excess water or solvents were present in
the wash step during SPE, resulting in low recoveries.
We previously reported [25] a validated off-line SPE/LC-MS method for quantifying BPA
levels in human aminiotic fluid. Based on this method, we further optimized the SPE
procedures under different pHs of loading sample, wash steps, and elution solvents. Since
both phthalate monoester and the phenolic compound of BPA are weak acids, acidifying
samples prior to SPE extraction will promote equilibrium to the unionized form and increase
the extraction efficiency. Therefore, 10 μl of formic acid was added to the samples prior to
SPE extraction. The addition of water in the acidified samples reduced the viscosity of the
sample, thus a better flow rate was achieved during the SPE sample loading step. After the
sample was loaded, the SPE cartridge was washed with 1.5 ml of water. No solvent was
added in this wash step to minimize any loss of MMP and/or MEP. After testing different
amounts of water to clean up the samples, it was determined that 1.5 ml of water was ideal
to wash out the interference of the sample matrix without sacrificing the recovery. Since
there are trace levels of MBP and MEHP detected in solvents, solvents from different
vendors were compared. Methanol from JT Baker and Sigma, acetonitrile from JT Baker,
Sigma, Alfa Aesar (Ward Hill, MA, USA) and Honeywell Burdick & Jackson (Muskegon,
MI, USA) and ethyl acetate from JT Baker were compared as eluent solvents. For each
solvent, 2 ml was dried under N2 and peak areas of MBP and MEHP were compared.
Acetonitrile from JT Baker gave the smallest peak, so it was chosen as the “elution solvent”.
Acetonitrile as an elution solvent was applied in volumes of 1, 1.5 and 2 ml, and recoveries
were similar. In order to reduce the use of organic solvents and the contamination from the
solvents, 1 ml of acetonitrile was chosen. We used 0.1% acetic acid in water with 10%
acetonitrile as the reconstituting solution because acetonitrile increases the signal of BPA
and won’t cause early elution of MMP in chromatograms.
3.2 Optimization of LC-MS conditions
In addition to the recoveries from the SPE steps, detection of both BPA and phthalate
monoester metabolites under the same LC and MS conditions with good sensitivity was a
challenge during method development. We first optimized the MS conditions. The negative-
ion ESI MS/MS product-ion spectra of each analyte and its IS were obtained by direct
infusion of the analyte solutions via a tee connection between the LC and the mass
spectrometer. After the mass spectrometer operating parameters were optimized, methods
using the most abundant product ion of each analyte were selected to build the MRM
method. Final MRM transitions were selected on the basis of signal to noise ratio (S/N) with
on-column injection analysis.
After the detection conditions were optimized, experiments were conducted to optimize the
chromatographic conditions. We investigated several reversed phase columns, including
Water’s XTerra MS C18 (100 mm × 2.1 mm, 3.5 μm), YMC pro-C18 (100 mm × 2.1 mm, 3
μm), Zorbax Eclipse XDB-C8 (150 mm × 4.6 mm, 5 μm), Phenomenex Synergi polar RP
(100 mm × 2.0 mm, 4 μm), Thermo Betasil C18 (100 mm × 2.1 mm, 3.5 μm) and Thermo
Betasil Phenyl (50 mm × 2.1 mm, 3.5 μm). The retention time, analyte response, peak
shapes, resolution, and background interference of these columns were compared using the
same mobile phase with optimized gradients. Thermo Betasil Phenyl (50 mm × 2.1 mm, 3.5
μm) showed superior peak shape with adequate retention time for each analyte compared to
other columns tested.
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The LCMS/MS methods reported so far for analyzing BPA contain no organic acid in the
mobile phase since they can suppress the signal of BPA [15,16,26]. Similarly, no mobile
phase additives, such as formic acid, acetic acid, ammonium acetate or ammonia were added
in our previous method [25] because we also found that they can cause severe signal
suppression for BPA analysis. However, these methods could not be applied to analyze
phthalate metabolites under the same analytical conditions since without organic acid (such
as acetic acid) added in the mobile phase, the phthalate monoesters, especially MMP, MEP,
MBP and MBzP, wouldn’t bind effectively to the stationary phase of the analytical column
and eluted out in 2 mins. After testing HPLC mobile phase with different additives, the
mobile phase containing 0.1% acetic acid resulted in adequate retention time and good
separation for phthalate metabolites and BPA. Acetonitrile and methanol were compared as
the organic part of the mobile phase. Acetonitrile was chosen because it had slightly higher
resolution and better peak shapes for phthalate monoesters than methanol. Since the
instrument used in the current method is more sensitive than the LC-MS system used in our
previous method [25], and sample clean up by SPE also effectively reduced the interference
from matrix, we were able to achieve a good sensitivity for BPA using mobile phase
containing 0.1% acetic acid. The HPLC elution gradients and the flow rate were also
optimized. The best chromatographic conditions were obtained using acetonitrile with 0.1%
acetic acid as mobile phase B and 0.1% acetic acid in water as mobile phase A starting the
gradient from 5% to 100% at a flow rate of 220 μl/min. This elution gradient can separate
analytes from potential interferences with less background noise and gives the best and most
robust chromatographic peaks, as shown in Fig. 1. The total run time was 12 min.
Stable isotopic labeled standards are internal standards, as they have the same physical and
chemical properties as the analyte. We chose 13C4-labeled phthalate monoester metabolites
except MEHP (its IS is D4-MEHP) and 13C12-BPA as ISs for the quantitation experiments
and added them at the beginning of the sample preparation. The addition of IS reduced
variations in sample preparation and injection, minimized matrix effects on quantitation, and
improved peak identification by providing a chromatographic reference (retention time
reference) for peak selection of the analytes, especially at trace level analysis.
3.3 Assay validation
Because it is readily available in sufficient amounts for analysis, urine is an important matrix
for biological monitoring of phthalates and BPA exposure in humans. The metabolite
concentrations are also higher in urine than in blood due to their relatively rapid metabolism
and excretion. However, matrix effects from biological matrices such as urine may impair
the accuracy and the precision of the method. During our initial method development based
on the previous method [25], we had difficulty in detecting low levels of MMP, MEP, BPA
and their ISs using 500-μl sample volume. Increasing the urine volume to 1ml decreased the
sensitivity and therefore did not solve this problem. Matrix effects on analyte responses
were therefore investigated using different urine sample volumes (200, 500 and 1000μl).
Results indicated severe ME as the urine sample volume increased (Fig. 2). Decreasing the
volume of reconstituted solution and increasing the injection volume also resulted in
substantial ME. In order to reduce ME, 200μl urine was selected as the sample volume in
this study. Dilution of extracts by increasing the volume of reconstituted solution from 110
to 150μl, and reducing the volume of sample injected from 20 to 10μl were found to reduce
the ME significantly and resulted in quantifiable low levels of MMP, MEP and BPA signals.
Matrix effect was further assessed at 10 and 100 ng/ml phthalate metabolites and BPA in
urine. Ion suppression of the analyte responses of MMP (75.2-77.2%) and MEP
(85.6-88.6%) was observed. Minor ion enhancement, which may come from improved
ionization, was observed for MBP, MBzP and MEHP with less than 10% the average of
intensity of the analyte ions enhanced at both levels. Because isotope-labeled internal
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standards were used for each analyte in this study and the same degree of ion suppression/
enhancement was also observed in ISs at each of the corresponding analyte level, the
quantification based on the analyte/IS response ratios should not be influenced by the matrix
effect. The results indicate that the current method, including sample clean up and HPLC
separation, is adequate to minimize matrix effect on the MS ionization, and the remaining
matrix effect can be corrected by IS.
Table 1 shows the mean extraction process recoveries in urine at two concentration levels.
The recoveries of MBP, MBzP, MEHP and BPA were completed with values ranging from
94.6% to 105.3%, but were relatively lower for MMP and MEP, with mean recoveries of
69.8% and 85.2%, respectively. After subtracting the mean loss from matrix effects for
MMP (23.8%) and MET (12.9%), the remaining loss from the extraction was less than 10%.
Therefore, the loss in the recoveries of MMP and MEP during the sample analysis process is
mainly due to the matrix effect during ESI, while the loss of MMP and MEP during the SPE
extraction was less significant. Since the same degree of ion suppression was observed in
each IS at both concentration levels, the recovery using internal standardization by
calculating the ratio of analyte/IS brought the recovery values close to 100% for each
analyte. The results demonstrated that the extraction recovery was adequate to achieve the
accuracy and precision needed.
Calibrations were prepared in water based on the results of ME and recovery described
above. Any urinary matrix effect on the calibration curve was evaluated by analyzing the
standards prepared in water versus those spiked into human urine. The slopes of calibration
curves containing matrix-matched standards prepared in human urine showed no significant
difference from the slopes of calibration curves in water. Therefore, matrix effect was
sufficiently eliminated for the range of analyte concentrations measured, and subsequent
calibration curves used in this study were all prepared in water. The calibration curves
showed good linearity within the given concentration range 0.3-200 ng/ml for MMP, MEP,
MBzP and BPA, and 1-200 ng/ml for MBP and MEHP, with the correlation coefficient (r)
exceeding 0.99 (Table 2). The mean back-calculated concentrations of the standards were
between 94.2 and 106.1% of the theoretic values of analytes. The retention times and
linearity of 5 phthalate metabolites and BPA are shown in Table 1.
The LOD and LOQ for MMP, MEP, MBzP and BPA in a 200μl urine sample were 0.1 and
0.3 ng/ml, respectively. The LOD and LOQ for MBP and MEHP were 0.3 and 1.0 ng/ml,
respectively. Laboratory blanks were prepared in water to capture possible environmental
contamination of analytes from water or solvents, as well as contaminants released from
material used for sample preparation (including tubes, pipette tips and autosampler vials).
We found trace levels of MBP and MEHP in tested laboratory blank samples. Background
subtraction was used to correct for this minor contamination. Twelve replicates of lower
limit of quantification (LLOQ) samples were used to evaluate the precision and accuracy at
the low end of the assay range from three separate runs. The precisions were 4.2-11.1% and
the accuracies were 95-114%. This indicates acceptable precision and accuracy at LLOQ
levels for all analytes.
The intra- and inter-day precision and accuracy were evaluated using urine spiked with
phthalate metabolites and BPA at two different concentrations. The intra-day precision was
between 4.0 and 10.2%, and the inter-assay precision was between 3.7 and 9.5%. The intra-
assay and inter-assay mean accuracies, expressed as percents of theoretical, were between
98.1-110.1 % and 95.1-112.2% (Table 3). These values show the good accuracy and
reproducibility of this method and that it is therefore adequate for biomonitoring studies.
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The stability of the standard stock solutions at room temperature and − 20°C was established
for at least 6 hours and 90 days, respectively. The differences between the stored and fresh
solutions were ≤ 5%, indicating acceptable stability for these storage durations. The
phthalate monoester metabolites and BPA in urine under long-term (− 20 °C for 90 days)
and short-term (room temperature for 4 hr) storage conditions following three freeze-thraw
cycles were also investigated. There were no significant differences (≤ 8%) in the mean
analyte concentrations at each level of 10 and 100 ng/ml compared with initial mean values,
indicating analyte stability. Additionally, the stability of the extracted samples in
reconstituted solution in an autosampler was also evaluated, and samples were found to be
stable at 4 °C at least for 24 hr. These results showed that degradation of analytes in urine is
negligible within the time required for analyzing the samples. Phthalate metabolites and
BPA also had acceptable stability under these test conditions.
3.4 Application of the assay
The LC-MS/MS method described above has been applied to the analysis of 50 human urine
samples collected from anonymous adult volunteers with possible exposure to phthalates in
their workplaces. Table 4 presents the summary of five phthalate monoester metabolites and
BPA levels found in these samples. Overall, the detectable rates of MMP, MEP, MBP,
MBzP, MEHP and BPA were 88, 100, 86, 100, 100 and 87%, respectively. The median
levels of MMP, MEP, MBP, MBzP, MEHP and BPA in all urine samples were 2.8, 43.7,
10.2, 4.7, 5.9 and 1.9 ng/ml, respectively. The geometric mean without creatinine
adjustments for MEP and MBzP levels in human urine were lower, and MBP and MEHP
levels were a little higher than the reported levels in urine [3]. The geometric mean of MMP
and BPA levels were comparable to the reported levels. This study confirmed detectable
levels of 5 phthalate metabolites and BPA in human urine samples.
4. Conclusions
We have developed an LC-MS/MS method for simultaneously analyzing 5 phthalate
monoester metabolites and BPA in human urine. The method has proven to be sensitive,
accurate and precise using a small sample volume of 200-μl, with a relatively short
chromatographic run time of 12 min. These results have demonstrated the value of this
method in assessing human exposure to phthalates and BPA in future studies.
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Highlights
• A LC-MS/MS method for simultaneously analyzing 5 phthalate monoester
metabolites and BPA in human urine is developed.
• The method was validated and demonstrated to be sensitive, accurate and
precise using 200 μl sample volume with a run time of 12 min.
• This method has been used successfully in assessing the exposure of phthalate
and BPA in 50 humans.
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Fig. 1.
Representative LC-MS/MS chromatograms of a standard solution containing 5 phthalate
metabolites and BPA at 10 ng/ml (A) and a non-spiked human urine extract (B) with
detected concentrations (in ng/ml) of below LOQ (MMP), 186.0 (MEP), 10.3 (MBP), 9.44
(MEzP), 6.0 (MEHP) and 0.9 (BPA).
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Fig. 2.
Influence of human urine sample volume used during SPE extractions on the matrix effect
(%) of 5 phthalate monoester metabolites and BPA. The volumes investigated were 200, 500
and 1000 μl.
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Table 1
The mean extraction process recovery of five phthalate metabolites and BPA in fortified human urine (n=5)
Analytes
Recovery (%)a ME (%)b
10ng/ml 100ng/ml 10ng/ml 100ng/ml
MMP 70.8 ± 10.5 68.7 ± 9.4 75.2 ± 9.3 77.2 ± 8.0
M EP 84.3 ± 5.8 86.1 ± 10.5 88.6 ± 6.0 85.6 ± 9.1
MBP 101.9 ± 8.0 95.3 ± 2.2 105.3 ± 7.0 103.5 ± 5.9
MBzP 103.2 ± 3.3 98.9 ± 5.1 106.9 ± 4.7 108.9 ± 6.8
MEHP 104.9 ± 6.3 105.3 ± 7.5 107.7 ± 11.3 110.0 ± 8.8
BPA 94.6 ± 6.1 100.3 ± 5.9 99.1 ± 4.4 100.8 ± 5.0
a
Recovery (%) expressed as mean ± standard deviation
b
Matrix effect (%) expressed as mean ± standard deviation
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Table 2
Retention times, quantitation ranges, and correlation coefficients for five phthalate metabolites and BPA.
Analytes tR (min) Quantitation range (ng/ml) Correlation coefficient (r)
MMP 2.28 0.3-200 0.996
MEP 2.75 0.3-200 0.993
MBP 3.87 1.0-200 0.997
MBzP 4.30 0.3-200 0.997
MEHP 5.68 1-200 0.997
BPA 4.12 0.3-200 0.998
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Table 3
Intra- and inter-day precision and accuracy for five phthalate metabolites and BPA.
Intra-day (ng/ml) (n=5) Inter-day (ng/ml) (n=15)
Analysis 10.0 100.0 10.0 100.0
MMP Mean 10.6 98.1 10.2 96.9
SD 1.0 9.6 0.8 7.9
Precision (%) 9.4 9.8 6.9 8.2
Accuracy (%) 106.2 98.1 102.3 96.9
MEP Mean 9.8 106.6 9.5 107.0
SD 1.0 9.2 0.9 10.1
Precision (%) 10.2 8.6 9.5 9.4
Accuracy (%) 98.1 106.6 95.1 107.0
MBP Mean 10.7 105.5 10.3 104.9
SD 0.7 6.3 0.5 4.7
Precision (%) 6.5 6.0 4.8 4.2
Accuracy (%) 107.3 105.5 103.2 104.9
MBzP Mean 9.9 98.3 9.9 97.5
SD 0.5 3.9 0.6 3.6
Precision (%) 5.1 4.0 6.0 3.7
Accuracy (%) 99.0 98.3 99.3 97.5
MEHP Mean 11.0 108.1 11.2 106.3
SD 0.8 7.2 0.7 5.9
Precision (%) 7.3 6.9 6.2 5.6
Accuracy (%) 110.1 108.1 112.2 106.3
BPA Mean 10.1 99.2 10.4 99.5
SD 0.6 5.4 0.5 4.5
Precision (%) 5.9 5.4 4.8 4.5
Accuracy (%) 101.2 99.2 104.4 99.5
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Table 4
Urinary concentrations of 5 phthalate metabolites and BPA detected in adult human spot urine samples (n=50)
Analytes
Concentrations (ng/ml)
Range Median Mean Geometric Mean
MMP
MEP
MBP
MBzP
MEHP
BPA
<LOQ – 14.2
5.3 – 906
<LOQ – 156
0.4 −23.3
2.3 – 34.1
<LOQ – 11.2
2.8
43.7
10.2
4.7
5.9
1.9
3.6
118.8
22.5
7.0
7.5
2.5
1.8
56.5
9.1
4.0
6.5
2.2
<LOQ: below limit of quantitation
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